Michael Catelani
Director of Finance/CFO at ANIXA BIOSCIENCES, INC.
Net worth: 90 358 $ as of 2024-03-30
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Amit Kumar | M | 59 | 12 years | |
Peter Francis | M | 68 |
Benitec Biopharma Ltd.
Benitec Biopharma Ltd. BiotechnologyHealth Technology Benitec Biopharma Ltd. engages in the development of proprietary therapeutic technology platform. It focuses on chronic and life-threatening human disease areas such as oncology, orphan disease, retinal disease, and infectious disease. The company was founded in 1997 and is headquartered in Melbourne, Australia. | 18 years |
Lewis Titterton | M | 79 | 25 years | |
Emily Gottschalk | F | 63 | 5 years | |
Arnold Baskies | M | 74 | 8 years | |
Pamela Garzone | M | 69 | 3 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
John Monahan | M | 77 |
Tacere Therapeutics, Inc.
Tacere Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tacere Therapeutics, Inc. provides treatment of infectious diseases. It develops novel therapeutics for the treatment of serious infectious diseases such as Hepatitis C (HCV). The company was founded by Sara M. Hall, Amit J. Kumar, John James Monahan, and Michael J. Catelani in 2006 and is headquartered in San Jose, CA. | 12 years |
Robert Berman | M | 61 | 5 years | |
Richard H. Williams | M | 87 | 1 years | |
David Cavalier | M | 54 | 3 years | |
Henry P. Herms | M | 78 | 16 years | |
Bruce F. Johnson | M | 81 | 1 years | |
Raymond Laurence Whitten | M | - |
Benitec Biopharma Ltd.
Benitec Biopharma Ltd. BiotechnologyHealth Technology Benitec Biopharma Ltd. engages in the development of proprietary therapeutic technology platform. It focuses on chronic and life-threatening human disease areas such as oncology, orphan disease, retinal disease, and infectious disease. The company was founded in 1997 and is headquartered in Melbourne, Australia. | 4 years |
Sara Cunningham | F | - |
Benitec Biopharma Ltd.
Benitec Biopharma Ltd. BiotechnologyHealth Technology Benitec Biopharma Ltd. engages in the development of proprietary therapeutic technology platform. It focuses on chronic and life-threatening human disease areas such as oncology, orphan disease, retinal disease, and infectious disease. The company was founded in 1997 and is headquartered in Melbourne, Australia. | 2 years |
John W. Rawling | M | - |
Benitec Biopharma Ltd.
Benitec Biopharma Ltd. BiotechnologyHealth Technology Benitec Biopharma Ltd. engages in the development of proprietary therapeutic technology platform. It focuses on chronic and life-threatening human disease areas such as oncology, orphan disease, retinal disease, and infectious disease. The company was founded in 1997 and is headquartered in Melbourne, Australia. | 5 years |
John Aiken McKinley | M | - |
Benitec Biopharma Ltd.
Benitec Biopharma Ltd. BiotechnologyHealth Technology Benitec Biopharma Ltd. engages in the development of proprietary therapeutic technology platform. It focuses on chronic and life-threatening human disease areas such as oncology, orphan disease, retinal disease, and infectious disease. The company was founded in 1997 and is headquartered in Melbourne, Australia. | 3 years |
Dale Fox | M | 56 | 3 years | |
Alexander Cappello | M | 68 |
Benitec Biopharma Ltd.
Benitec Biopharma Ltd. BiotechnologyHealth Technology Benitec Biopharma Ltd. engages in the development of proprietary therapeutic technology platform. It focuses on chronic and life-threatening human disease areas such as oncology, orphan disease, retinal disease, and infectious disease. The company was founded in 1997 and is headquartered in Melbourne, Australia. | 1 years |
Yasuo Urata | M | 68 |
Tacere Therapeutics, Inc.
Tacere Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tacere Therapeutics, Inc. provides treatment of infectious diseases. It develops novel therapeutics for the treatment of serious infectious diseases such as Hepatitis C (HCV). The company was founded by Sara M. Hall, Amit J. Kumar, John James Monahan, and Michael J. Catelani in 2006 and is headquartered in San Jose, CA. | - |
Trent A. Basarsky | M | 56 |
Axon Instruments, Inc.
Axon Instruments, Inc. Medical SpecialtiesHealth Technology Axon Instruments, Inc. manufactures instruments and software for drug discovery and academic research. The company is based in Union City, CA. Axon Instruments was acquired by Molecular Devices LLC, part of Danaher Corp. from March 28, 2007 on July 01, 2004 for $128.27 million. | 6 years |
David Suhy | M | - |
Tacere Therapeutics, Inc.
Tacere Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tacere Therapeutics, Inc. provides treatment of infectious diseases. It develops novel therapeutics for the treatment of serious infectious diseases such as Hepatitis C (HCV). The company was founded by Sara M. Hall, Amit J. Kumar, John James Monahan, and Michael J. Catelani in 2006 and is headquartered in San Jose, CA. | 4 years |
Thomas Schlumpberger | M | - | 1 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 16 | 72.73% |
Australia | 6 | 27.27% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Michael Catelani
- Personal Network